• Quince Therapeutics formed a Scientific Advisory Board to support development of LAM-001, an inhaled rapamycin formulation aimed at improving pulmonary delivery while reducing systemic exposure.
• Paul Yu was named chairman; he is director of the Cardiovascular Research Center at Massachusetts General Hospital and an associate professor at Harvard Medical School.
• The board also includes:
  • Aaron Waxman, director of the Pulmonary Vascular Disease Program at Brigham and Women’s Hospital
  • Steven Nathan of Inova’s Advanced Lung Disease and Lung Transplant Program
  • Steve Hays, medical director of UCSF’s Advanced Lung Disease and Lung Transplant Program
  • Robert Baughman, professor emeritus at the University of Cincinnati
• The advisory group will help guide LAM-001 development across pulmonary indications including PH-ILD, BOS post lung transplant, and SAPH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754351) on June 30, 2026, and is solely responsible for the information contained therein.